Medivir gets 2 MUSD from Chiron as phase I clinical trial has been started with the HIV antiviral substance MIV-150

Medivir gets 2 MUSD from Chiron as phase I clinical trial has been started with the HIV antiviral substance MIV-150 Medivir receives a 2 MUSD milestone payment from Chiron Corporation following the start of phase I clinical trials in the UK. Earlier this year Medivir out licenced the HIV antiviral substance MIV-150 to Chiron Corporation. The agreement gave Chiron the exclusive rights to the global marketing and sales of the HIV drug MIV-150. Medivir received 5 MUSD on signing. If MIV-150 is successful, Medivir would receive up to a total of 35 MUSD upon reaching specified milestones, as well as royalties up to the year 2017, under the Chiron contract. In total Medivir has now received 12,6 MUSD this year for this project. Huddinge 18 October 1999 Medivir AB (publ) For more information please contact: Anna Bernsten, Vice President Business Development and Investor Relations, Medivir AB, phone no +46-8-608 31 05, +46-709-369 069 or e-mail: anna.bernsten@medivir.se. For more information about Medivir: www.medivir.se Medivir is a research and development company which develops new and better substances for the treatment of infectious diseases. The subsidiary company CCS AB develops, manufactures and markets body-care products and pharmaceuticals. The Group consists of the parent company, Medivir AB, the CCS AB subsidiary and UK company CCS (UK) Ltd. ------------------------------------------------------------ Please visit http://www.bit.se for further information The following files are available for download: http://www.bit.se/bitonline/1999/10/18/19991018BIT00070/bit0001.doc http://www.bit.se/bitonline/1999/10/18/19991018BIT00070/bit0002.pdf